Saskatchewan to Fund Elahere and Keytruda for Ovarian Cancer
Public coverage for eligible advanced ovarian cancer patients begins December 1, 2026, according to the Saskatchewan government.
Updated on Nov. 22, 2026 in Cancer

Live Poll
Should provincial governments publicly cover expensive new cancer drugs for patients?
The Saskatchewan government will provide public coverage for Elahere and Keytruda for eligible patients with advanced ovarian cancer, starting December 1, 2026. The treatments are for patients whose cancer has stopped responding to standard therapies, including chemotherapy.
Why it matters
The coverage aims to remove financial barriers for eligible women who could benefit from the treatments. Clinical studies show the medications can help eligible patients live longer and delay disease progression.
Approximately eight to 10 Saskatchewan patients each year are expected to benefit from the two medications, based on provincial estimates. The Saskatchewan Cancer Agency received a budget of $308.6 million for the 2026-27 fiscal year, though the source does not say how much of that will go toward these drugs.
The players
Saskatchewan government
The provincial government of Saskatchewan, which announced public funding for the two ovarian cancer medications.
Ovarian Cancer Canada
A national charity focused on ovarian cancer awareness, research and support, which welcomed the announcement.
The details
Elahere and Keytruda will be publicly funded for eligible Saskatchewan patients whose advanced ovarian cancer has progressed despite standard treatment. Pricing was negotiated through the pan-Canadian Pharmaceutical Alliance on behalf of participating public drug plans, following national assessments of safety, effectiveness and value.
Timeline
December 1, 2026: Public coverage for Elahere and Keytruda begins in Saskatchewan.
2026-27 fiscal year: The Saskatchewan Cancer Agency operates on a budget of $308.6 million.
National Context
Saskatchewan's coverage follows prices negotiated through the pan-Canadian Pharmaceutical Alliance, the national body that negotiates drug prices for participating public plans. Ovarian Cancer Canada hopes other provinces will make similar coverage decisions.
Women with advanced ovarian cancer whose disease has stopped responding to standard therapies may now have publicly funded access to these medications in Saskatchewan. Those currently receiving ovarian cancer treatment are encouraged to discuss the options with their oncologist.
The takeaway
Eligible Saskatchewan women with advanced ovarian cancer should talk with their oncologist about whether Elahere or Keytruda is appropriate before the December 1, 2026 start date. Coverage decisions depend on eligibility, so confirming criteria with a care team is the next practical step.
What happens next
Public coverage for Elahere and Keytruda begins December 1, 2026, for eligible Saskatchewan patients.
Further reading
Explore more on Cancer coverage and treatment access.
Source note: This article includes information reported by WestCentralOnline.
Live Poll
Should provincial governments publicly cover expensive new cancer drugs for patients?






